Physician profile
Stefan A Willging
NPI 1679523518
$14,304.57
in general payments reported to CMS, 2019-2025
79 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,659 · 2020: $1,844 · 2021: $2,382 · 2022: $2,116 · 2023: $2,282 · 2024: $1,989 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,228 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,228.17 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,108.92 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $942.45 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $888.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $819.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $800.55 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $760.19 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Gilead Sciences, INC. | $693.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $656.76 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $625.62 | 2019-2025 | Spravato |
| Pfizer INC. | $614.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.96 | 2019-2024 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $339.46 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $303.78 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $276.94 | 2021-2024 | |
| Allergan, INC. | $243.58 | 2019-2020 |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Willging listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.